Pyxis Oncology, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (3)

Latest Posts

About This Stock More About This Stock
Week In Review: RemeGen Raises $410 Million In Shanghai IPO For MAbs/Dual Therapies
Article By: ChinaBio® Today
Saturday, April 2, 2022 12:45 PM EDT
RemeGen, a Yantai biotech with a portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Although the offering was oversubscribed, the company’s stock slipped 10% lower in the first two days of trading.
In this article: LLY, 1801.HK, 2137.HK, 1228.HK, 2616.HK, 9969.HK, 9995.HK, PYXS
Read

Latest Tweets for $PYXS

No tweets yet!

PARTNER HEADLINES